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Abstract
Background: Pediatric epilepsy, including treatment-resistant forms, has a major effect on the quality of life,
morbidity, and mortality of affected children. Interest has been growing in the use of medical cannabis as a
treatment for pediatric epilepsy, yet there has been no comprehensive review of the benefits and harms of
cannabis use in this population. In this systematic review, we will search for, synthesize, and assess the published
and gray literature in order to provide usable and relevant information to parents, clinicians, and policy makers.
Methods: We will perform a living systematic review of studies involving the use of cannabis to treat pediatric
epilepsy. We will search the published and gray literature for studies involving children with any type of epilepsy
taking any form of cannabis. Studies will be selected for inclusion by two independent reviewers. The primary
outcome is seizure freedom. Secondary outcomes are seizure frequency, quality of life (child, caregiver), quality and
quantity of sleep, status epilepticus, tonic-clonic seizures, death (all-cause, sudden unexpected death in epilepsy),
gastrointestinal adverse events (diarrhea, vomiting), and visits to the emergency room. The quality of each included
study will be assessed. If data are sufficient in quantity and sufficiently similar, we will conduct pairwise random-effects
meta-analysis. We will repeat the literature search every 6 months to identify studies published after the previous search
date. Sequential meta-analysis will be performed as necessary to update the review findings.
Discussion: Our review aims to provide a comprehensive and up-to-date summary of the available evidence to inform
decisions about the use of cannabis in children with treatment-resistant epilepsy. The results of this review will be of use
to parents, clinicians, and policy makers as they navigate this rapidly evolving area.
Systematic review registration: PROSPERO CRD42018084755
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Background
Interest in the use of cannabis for pediatric epilepsy has
grown over the last decade, driven in part by media
reports of children whose treatment-resistant epilepsy
has responded to cannabis [1]. The well-publicized case
of Charlotte Figi, whose parents started her on medical
cannabis at age 5, is not unique [2], and many parents of
children with treatment-resistant epilepsy have reported
turning to alternative treatments [3], both with and
without the aid of medical professionals. In particular,
parents of children with treatment-resistant epilepsy (an
inadequate response to two or more adequate trials of
antiepileptic drugs [4]), which affects between 28 and
37% of people with epilepsy [5], have expressed great
interest in the use of cannabis for the treatment of their
children’s epilepsy [3]. Indeed, pediatric treatment-resistant
epilepsy has potentially catastrophic consequences, includ-
ing cognitive delay, behavioral problems, autism, poor
quality of life, and early death [6–9].
Despite the recorded medicinal use of cannabis dating
back to the second century BCE [10], there has been
relatively little research into its effectiveness or safety,
likely owing to its illegal status in many jurisdictions. In
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adults, cannabis has been reported to be effective in the
treatment of nausea and vomiting due to chemotherapy,
chronic pain, spasticity associated with multiple sclerosis,
sleep disorders, and Tourette syndrome, with inconclusive
evidence for its use in appetite stimulation in patients with
HIV/AIDS, anxiety disorders, and glaucoma [11]. There is
relatively little clinical evidence to support the use of
cannabis in the treatment of pediatric epilepsy, and there
are large discrepancies between the beliefs of health care
professionals and the general public with respect to its
effectiveness and safety [12]. A 2014 Cochrane review of
the use of cannabinoids for the treatment of epilepsy
included four small low-quality randomized controlled
trials (RCTs), none of which involved children [13]. At the
time of this review, the authors concluded that there was
insufficient evidence to make reliable conclusions about
the efficacy or long-term safety of cannabinoids for the
treatment of epilepsy [13]. However, the evidence base
in this area is changing rapidly, and recently published
studies have suggested a beneficial effect of cannabis in
this population [14, 15], although the mechanisms
underlying this response are not clear [16].
The use of cannabis in the treatment of pediatric epilepsy
is an ideal topic for a living systematic review because it is
a priority for decision-making, there is little certainty in the
existing evidence base, and there is rapidly accumulating
evidence [17]. Living systematic reviews are a relatively
new approach to continually updating systematic reviews,
with new evidence being incorporated as it becomes avail-
able [17]. Unlike traditional systematic review updates,
which may be undertaken infrequently, living systematic
reviewers search for new studies at a priori-defined inter-
vals and follow a set protocol for determining whether up-
dated analysis and publication are warranted. At present,
37 studies involving the use of various forms of cannabis
for the treatment of pediatric epilepsy are registered in
ClinicalTrials.gov, suggesting that there will be an
abundance of new data in the coming years.
In this living systematic review, we will comprehen-
sively search the published and gray literature for studies
that have evaluated the benefits and harms of cannabis
for pediatric epilepsy. The results of our review will be
of use to parents, clinicians, and policy makers in mak-
ing treatment decisions for children with epilepsy.
Methods/design
This systematic review protocol has been submitted to
PROSPERO (CRD42018084755) and follows the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses
Protocols (PRISMA-P) statement (Additional file 1) [18].
Patient involvement
Two family members of children with epilepsy were
involved in selecting the outcome measures for inclusion
in this systematic review and are co-authors of this
protocol (CA, AR).
Search strategy
A search of the published and gray literature will be per-
formed by an experienced medical information specialist
to identify studies involving the use of cannabis for the
treatment of pediatric epilepsy. The search strategy
was developed in consultation with an experienced
medical information specialist and the research team
(Additional file 2). The search will be peer-reviewed by
another librarian by use of the Peer Review of Electronic
Search Strategies (PRESS) checklist [19]. Using the OVID
platform, we will search Ovid MEDLINE®, including Epub
Ahead of Print and In-Process & Other Non-Indexed
Citations, Embase Classic + Embase, and PsycINFO. We
will also search the Cochrane Library on Wiley. The
search strategies will use a combination of controlled
vocabulary (e.g., “Epilepsy”, “Cannabinoids”, “Medical
Marijuana”) and keywords (e.g., “seizure”, “cannabis”,
“THC”). Vocabulary and syntax will be adjusted across
databases. No date or language restrictions will be
imposed. Gray literature will be searched by use of
CADTH’s Gray Matters Light [20], Google Scholar, the
clinical trials registries ClinicalTrials.gov, and the ICTRP
Search Portal of the World Health Organization.
Eligibility criteria
Studies will be eligible for inclusion if they meet the
population, intervention, comparator, and study design
criteria described below. Studies will not be selected
based on reported outcomes.
Population
The population includes children (aged 18 years or
younger) with any form of epilepsy. Studies that report
mixed populations of children and adults will be included
if they report data separately for participants aged less
than 19 years or if, based on descriptive statistics, we can
determine that at least 60% of patients are aged less than
19 years.
Intervention
The intervention is any type of cannabis (synthetic or
natural), cannabinol, cannabidiol [CBD], tetrahydro-
cannabinol [THC], or combinations of these agents.
The intervention may be administered by any route
(e.g., oral, inhalation), include any strain of cannabis,
and any ratio of THC to CBD.
Comparators
Eligible comparators include pharmacologic and non-
pharmacologic treatments for epilepsy, including anti-
epileptic drugs, diet therapy, vagus nerve stimulation,
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and resective brain surgery. Comparators may also include
placebo, usual care, or no treatment.
Outcomes
The primary outcome is seizure freedom. Secondary
outcomes are seizure frequency, quality of life (child,
caregiver), improvement or worsening of sleep, status
epilepticus, tonic-clonic seizures, death (all-cause, sud-
den unexpected death in epilepsy), gastrointestinal ad-
verse events (diarrhea, vomiting), and visits to the
emergency room. Study eligibility will not be evaluated
based on reported outcomes.
Study designs
Eligible study designs are RCTs (including cross-over
and N-of-1 trials), quasi-randomized controlled trials,
controlled before-after, non-randomized controlled trials,
historically or concurrently controlled cohort series [pro-
spective or retrospective], case-control studies, uncontrolled
cohort studies, case series involving at least five patients,
and cross-sectional studies. Conference abstracts and clinical
trial registrations will be eligible for inclusion.
Screening and selection procedure
Two independent reviewers will screen the title and
abstract of each identified record and assess the eligibility
against the above criteria. The full text of any record
deemed potentially relevant by at least one reviewer will
be examined in detail and evaluated for eligibility by two
independent reviewers. Disagreements on eligibility will
be resolved by discussion. Studies will not be excluded
based on treatment duration, and no language exclusions
will be applied. All screening and data extraction will
be performed using standardized and piloted forms in
Distiller SR (Evidence Partners).
Data extraction
Data will be extracted by one reviewer and checked for
accuracy by a second reviewer. Data to be extracted
includes study characteristics (e.g., first author, year of
publication, study design, country of study), participant
characteristics (e.g., age, sex, epilepsy syndrome, ethnicity,
comedications, comorbidities), intervention and compara-
tor details (e.g., type of treatment, dose, route of administra-
tion, duration), and outcome data at the longest duration of
follow-up. Event counts will be extracted for dichotomous
outcomes (seizure freedom, improvement or worsening of
sleep, status epilepticus, deaths, diarrhea, vomiting,
visits to the emergency room). Data for continuous out-
comes (seizure frequency, quality of life, quality and/or
quantity of sleep) will be extracted as mean or median
change from baseline or difference between groups
after treatment. If available, the number of participants
who achieve at least a 50% reduction in seizures from
baseline will be extracted. Estimates of variability (e.g.,
standard deviation, standard error, 95% confidence
intervals) will be extracted. First-period data as well as
end-of-study effects will be extracted from cross-over
studies. Additional information will be extracted, including
the number of cases and controls (case-control studies),
adjusted odds ratios, relative risk or hazard ratios, and
95% confidence intervals, as reported by the study authors.
No data will be extracted from studies that do not present
study-specific data (e.g., odds ratios, 95% confidence inter-
vals) or provide sufficient information for calculation of an
outcome measure (event counts and denominators).
Quality and risk of bias assessment
The quality of included studies that report at least one
outcome of interest will be assessed by use of the
Cochrane Collaboration’s Risk of Bias tool for RCTs [21].
The Institute of Health Economics Quality Appraisal
Checklist for Case Series Studies [22], or SIGN50 [23]
will be used for other study designs as appropriate.
Other quality assessment tools will be identified as
needed depending on the designs of the included stud-
ies. Quality will be assessed by two independent re-
viewers, and disagreements will be resolved by
discussion.
Data synthesis
First, we will provide a descriptive summary of study
selection, study and patient characteristics, and the results
of the quality assessment.
Second, we will assess whether the data are sufficient
in quantity and sufficiently homogeneous to be pooled
via random-effects meta-analyses (i.e., minimal clinical,
methodological, statistical heterogeneity). We will assess
clinical heterogeneity by examining the patient character-
istics of the included studies and methodological hetero-
geneity by assessing the study characteristics. Statistical
heterogeneity will be assessed by use of the I2 statistic. If
substantial heterogeneity is present (I2 > 75%), we will
explore this by subgroup analyses. At I2 values above 75%,
pooled data will not be reported, and descriptive summar-
ies of the study-level findings will be presented. The
primary analysis will involve data from RCTs involving
children (at least 80% of participants aged less than
19 years) with any type of epilepsy, and data from other
study designs will be evaluated in secondary analyses if
deemed appropriate. Other secondary analyses will involve
(a) studies including participants with treatment-resistant
epilepsy or (b) studies in which at least 60% of the popula-
tion is aged less than 19 years. If data are sufficient and
sufficiently similar, meta-analysis will be performed by use
of RevMan (v.5.3; Cochrane Collaboration). If there are in-
sufficient data for meta-analysis, we will report descriptive
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summaries for each outcome. The findings of conference
abstracts will be summarized descriptively.
Additional analyses
If sufficient data are available, sensitivity analyses will be
performed to test the robustness of the estimates. For
example, we will look at the impact of excluding studies
with high risk of bias or poor methodological quality.
We will also assess the impact of comedications; study
location; and cannabis strain, dose, level of THC, or ratio
of THC to CBD; or route of administration, depending on
data availability. Subgroup analyses will investigate the
effect of epilepsy syndrome (e.g., Dravet syndrome,
Lennox-Gastaut syndrome), age, and sex. Publication
bias will be assessed by visual inspection of funnel plots
for outcomes that have data from at least ten studies [24].
Quality of the evidence
The quality of the evidence will be assessed for each
outcome by use of the Grades of Recommendations,
Assessment, Development and Evaluation (GRADE)
Working Group method [25].
Update plan
In keeping with current recommendations for the conduct
of living systematic reviews [17], the literature search will
be repeated at regular a priori-defined intervals to identify
newly available studies. Published and gray literature
searches will be updated every 6 months, and any records
identified after the date of the last update will be screened
for inclusion as described above. This frequency of updating
was chosen to maximize the visibility of new information
for decision-makers but to minimize the resources required
[17]. There are three potential update scenarios: (1) no new
evidence is located, (2) new evidence is located but is not
sufficient to trigger updated analysis and publication, or (3)
new evidence is located and new analysis and dissemination
is required [17]. If new studies that meet the eligibility
requirements are located, the reviewer team will decide, in
consultation with a clinical expert (BM), whether updated
analyses are required, with consideration of balancing the
needs of decision-makers with the available resources [17].
If required, meta-analyses will be updated by use of trial
sequential analyses (type I error, 0.05; power, 80%; assumed
effect size, moderate Cohen’s effect size [0.5 standard devia-
tions]) for living systematic reviews [26].
Discussion
Pediatric epilepsy has a major impact on the quality of
life for patients and their families. Interest in the use of
cannabis as a treatment for pediatric epilepsy and, in
particular, for treatment-resistant epilepsy has grown
over the last decade, driven in part by media reports of
children whose treatment-resistant epilepsy has responded
to cannabis after the failure of conventional treatments
[1]. This living systematic review will provide a compre-
hensive summary of the current evidence for the use of
cannabis for the treatment of pediatric epilepsy and will
incorporate new evidence as it becomes available. The
results will be of use to decision-makers, including parents
of affected children, clinicians, and policy makers.
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